HOME >> BIOLOGY >> NEWS
For sardine and anchovy, El Nio events do not always have the same effects

The warm El Nio episodes are generally accepted to be harmful to the development of cold-water anchovy populations, but favourable for abundant populations of sardine, adapted to warmer waters. IRD researchers and their Peruvian partners (1) have been studying fluctuations in pelagic fish populations in the world's richest oceanic ecosystems for fish, the Peru-Humboldt Current system, off Peru. They showed that the traditional explanation does not always hold true. During the 1997-98 El Nio event, one of the strongest of the XXth century, anchovy in fact adapted and reproduced by taking advantage of refuge habitat 'loopholes' located very close to the coast. The existence of these areas, with specifically different climatic conditions, appear to have favoured the survival of these populations in spite of generally unfavourable climatic conditions.

Near the coasts of Peru and Chile, the Humboldt Current ecosystem is the world's most productive fishing zone. This cold-current zone, with frequent coastal upwellings ( 2 ), occupies less than 1 % of the world's ocean surface and provides 15 to 20 % of global maritime catches. Unlike other large regions of upwelling, this ecosystem proves to be more exposed to variations in climate. Its geographical location brings it under the direct influence of disturbances generated by the El Nio-La Nia events which arise every 3 to 7 years. Other climatic cycles, called El Viejo-La Vieja by reference to the first two, also bear influence, but on a longer time-scale with a period of about 50 years. Large-scale alternation of abundance of sardine and anchovy populations corresponds to these warm (El Viejo) and cold (La Vieja) climatic regimes. At smaller scale, the El Nio events would induce massive die-offs in anchovy, adapted to cold, nutrient-rich coastal waters, whereas the populations of sardine (and of other species like jack mackerel or mackerel), which live in the warmer waters, would experience an upsurge
'"/>

Contact: Hlne Deval
presse@paris.ird.fr
33-148-037-519
Institut de Recherche Pour le Dveloppement
5-Apr-2005


Page: 1 2 3

Related biology news :

1. Critical protein prevents DNA damage from persisting through generations
2. Repair of DNA by Brca2 gene prevents medulloblastoma
3. Media events planned for 2007 American Society of Gene Therapy meeting, May 30-June 3
4. Vaccine prevents prion disease in mice
5. New compound prevents alcoholic behavior, relapse in animals by blocking stress response
6. Free public events at the 2007 AAAS Annual Meeting
7. Cold Spring Harbor Laboratory scientists discover new gene that prevents multiple types of cancer
8. Blood test predicts cardiac events and death in heart patients
9. Antibody therapy prevents type 1 diabetes in mice
10. Cambridge led team discovers gene mutation which prevents carriers from feeling pain
11. The abortion pill compound prevents breast tumor growth

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: For sardine and anchovy Nio events not always have the same effects

(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/20/2015)... PASADENA, Calif. , April 20, 2015 ... San Gabriel Valley to implant a new miniaturized, wireless ... HF System is the first and only FDA-approved heart ... reduce hospital admissions when used by physicians to manage ... a sensor that is implanted in the pulmonary artery ...
(Date:4/14/2015)... 2015  HYPR Corp. today announced it has ... Alliance tm , an industry consortium transforming online ... share technology and collaborate to deliver open specifications ... secure and private, and easier to use. ... protects sensitive user information and eliminates the dependency ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3
(Date:5/21/2015)... , May 21, 2015  The EveryLife Foundation ... (R-UT) and Amy Klobuchar (D-MN) ... Accelerating Cures & Treatments, or OPEN ACT. ... patient advocacy organizations, this bipartisan legislation promises to ... medicines to rare disease patients by incentivizing drug ...
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... May 20, 2015 Research and Markets ... of the "2015 Global Survey on Flow ... The primary goal of this research ... instruments and reagents. Key information the survey seeks ... of flow cytometers, predominantly used applications for flow ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: